" class="no-js "lang="en-US"> Abbisko Therapeutics - Medtech Alert
Friday, March 31, 2023

Breaking News

Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases Implantica Launches RefluxStop™ in Italy Granular Therapeutics to Accelerate Development of Next-Generation Pipeline for Treating Mast Cell Driven Diseases Xeris Biopharma Appoints Ricki Fairley to Board of Directors AskBio to Present Phase 1b Results Investigating AB-1005 as Treatment for Parkinson’s Disease New Imaging Method for Evaluating Transport of Oxygen to Blood Cells
Abbisko Therapeutics | Pharmtech Focus

Abbisko Therapeutics

About Abbisko Therapeutics

Abbisko Therapeutics

Related Story

Industry News

 Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules | Pharmtech Focus

Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules

January 18 2022

Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter), a subsidiary of Abbisko Cayman Limited (Stock Code: […]